Humacyte rustles up $12 million and a new chief executive

September 9, 2010 by MedCity News

Regenerative medicine firm Humacyte Inc. nets pharma vet Carrie Cox for CEO and a $12 million investment.

MedCity News logo

Duke University spin-off Humacyte Inc. landed a $12 million investment and pharmaceutical industry veteran Carrie Cox for CEO.

The Durham, N.C.-based regenerative medicine company recently raised $12 million from a single investor through a debt offering, according to an amended filing with the Securities & Exchange Commission. Another amended filing shows the company raised $7 million in debt about a year ago.

Humacyte founder and former CEO Dr. Laura Niklason would say only that "we have taken in funds from our existing investors," when asked by the Triangle Business Journal about the recent investments and their purposes.

Humacyte uses a proprietary technology to engineer human tissues that can be shaped into tubes, sheets and other forms to treat vascular diseases and repair the body. Niklason, a former Duke researcher, started the company in late 2004 to use human cells to make artificial blood vessels that could be transplanted into patients suffering from kidney failure and other ailments, the Triangle Business Journal said.

Cox, who had been executive vice president and president of Global Pharmaceuticals at Schering-Plough Corp., will assumer her new role on Sept. 20, according to Humacyte. She is expected to lead the young Research Triangle Park company from its development to its commercialization phase.

"We are clearly delighted to have an executive with the experience, leadership and sound business judgment of Carrie Cox to lead Humacyte at this important juncture in our company's history," Niklason said in prepared remarks. "Carrie is ideally qualified to oversee our ongoing product development efforts and lead us into commercialization of these much-needed treatment options for patients."